Articles
Vol. 65 No. 2 (2021)
The clinical significance of UBE2C gene in progression of renal cell carcinoma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 9 November 2020
Accepted: 10 February 2021
Accepted: 10 February 2021
1918
Views
894
Downloads
31
HTML
Authors
Renal cell carcinoma (RCC), with high morbidity and mortality, is one of the top ten serious cancers. Due to limited therapies and little knowledge about the mechanism underlying RCC, overall survival of RCC patients is poor. UBE2C is a member of ubiquitin modification system and promotes carcinogenesis in cancer, but its role in RCC is unknown. Based on the TCGA (The Cancer Genome Atlas) data, UBE2C was over-expressed in a total of 525 RCC tissues and displayed higher expression in advanced tissues (stage IV vs stage I, p<0.05). RT-qPCR and IHC analysis confirmed over-expression of UBE2C in 90 of clinical RCC tissues. Further, UBE2C was associated with clinical factors including TNM stage, gender, and pathological stage. And higher UBE2C expression predicted shorter overall survival and progression-free survival. Both univariate and multivariate COX analysis suggested UBE2C as a critical gene in RCC. Then GO and KEGG analysis showed that cell cycle and DNA replication pathways were two top signaling pathways affected by UBE2C. In vitro assay showed that knockdown of UBE2C in 786-O cells inhibited proliferation and migration significantly. Therefore, this study proves that UBE2C is an important gene in RCC and is essential to proliferation and migration of RCC.
Downloads
Download data is not yet available.
Citations
Nabi S, Kessler ER, Bernard B, Flaig TW, Lam ET. Renal cell carcinoma: a review of biology and pathophysiology. F1000Res 2018; 7:307. DOI: https://doi.org/10.12688/f1000research.13179.1
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. Ca Cancer J Clin 2018;68:7-30. DOI: https://doi.org/10.3322/caac.21442
Vecchio SJD, Ellis RJ. Cabozantinib for the management of metastatic clear cell renal cell carcinoma. J Kidney Cancer VHL 2018;5:1-5. DOI: https://doi.org/10.15586/jkcvhl.2018.109
Conti A, Santoni M, Amantini C, Burattini L, Berardi R, Santoni G, et al. Progress of molecular targeted therapies for advanced renal cell carcinoma. BioMed Res Int 2013;2013:419176. DOI: https://doi.org/10.1155/2013/419176
Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs 2018;78:1443-57. DOI: https://doi.org/10.1007/s40265-018-0970-y
Sanchez-Gastaldo A, Kempf E, Aranzazu GDA, Duran I. Systemic treatment of renal cell cancer: A comprehensive review. Cancer Treat Rev 2017;60:77-89. DOI: https://doi.org/10.1016/j.ctrv.2017.08.010
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer J Clin 2019;69:7-34. DOI: https://doi.org/10.3322/caac.21551
Hao Z, Zhang H, Cowell J. Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol 2012;33:723-30. DOI: https://doi.org/10.1007/s13277-011-0291-1
Zhang J, Liu XY, Yu GZ, Liu L, Wang JJ, Chen XY, et al. UBE2C is a potential biomarker of intestinal-type gastric cancer with chromosomal instability. Front Pharmacol 2018;9:847. DOI: https://doi.org/10.3389/fphar.2018.00847
Han QL, Zhou C, Liu F, Xu GH, Zheng R, Zhang X. MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. Oncol Rep 2015;34:877-83. DOI: https://doi.org/10.3892/or.2015.4049
Takahashi Y, Ishii Y, Nishida Y, Ikarashi M, Nagata T, Nakamura T, et al. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet Cytogen 2006;168:30-5. DOI: https://doi.org/10.1016/j.cancergencyto.2005.12.011
Martinez-Canales S, Miguel LDR, Nuncia-Cantarero M,Paez R, Amir E, Gyorffy B, et al. Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer. Cancer Med 2018;7:1896-907. DOI: https://doi.org/10.1002/cam4.1406
Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, et al. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer 2009;101:166-73. DOI: https://doi.org/10.1038/sj.bjc.6605122
Wang Z, Jensen MA, Zenklusen JC. A Practical Guide to The Cancer Genome Atlas (TCGA). Methods Mol Biol 2016;1418:111-41. DOI: https://doi.org/10.1007/978-1-4939-3578-9_6
Cheng PF, Dummer R, Levesque MP. Data mining the cancer genome atlas in the era of precision cancer medicine. Swiss Med Wkly 2015;145:w14183. DOI: https://doi.org/10.4414/smw.2015.14183
Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, et al. TNM staging of renal cell carcinoma. Cancer 1997;80:992-3. DOI: https://doi.org/10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q
Wei SQ, Li CY, Li BG, Li JM, Wang H. UBE2C siRNA inhibits proliferation and invasion of human castration resistant prostate cancer PC3 cells. Tumor 2015;11:1200-7.
Wang HY, Zhang CP, Rorick A, Wu DY, Chiu M, Thomas-Ahner J, et al. CCI-779 inhibits cell-cycle G2/M progression and invasion of castration resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability. Cancer Res 2011;71:4866-76. DOI: https://doi.org/10.1158/0008-5472.CAN-10-4576
Zhang HQ, Zhao G, Ke B,Ma G, Liu GL, Liang H, et al. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci 2018;22:1665-71.
Mo CH, Gao L, Zhu XF, Wei KL, Zeng JJ, Chen G, et al. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int 2017;17:83. DOI: https://doi.org/10.1186/s12935-017-0455-1
Hutson TE, Fiqlin RA. Renal cell cancer. Cancer J 2007;13:282-6. DOI: https://doi.org/10.1097/PPO.0b013e318156fe69
Yuan LS, Chen L, Qian KY, Qian GF, Wu CL, Wang XH, et al. Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC). Genom Data 2017;14:132-40. DOI: https://doi.org/10.1016/j.gdata.2017.10.006
Aze A, Maiorano D. Recent advances in understanding DNA replication: cell type-specific adaption of the DNA replication program. F1000Res 2018;7:F1000 Faculty Rev-1351. DOI: https://doi.org/10.12688/f1000research.15408.1
24.Deneke VE, Puliafito A, Krueger D, Narla AV, Simone AD, Primo L, et al. Self-organized nuclear positioning synchronizes the cell cycle in drosophila embryos. Cell 2019;177:925-41. DOI: https://doi.org/10.1016/j.cell.2019.03.007
Bjorklund M. Cell size homeostasis: metabolic control of growth and cell division. Biochim Biophys Acta Mol Cell Res 2019; 866:409-17. DOI: https://doi.org/10.1016/j.bbamcr.2018.10.002
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. DOI: https://doi.org/10.1016/S0092-8674(00)81683-9
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI: https://doi.org/10.1016/j.cell.2011.02.013
How to Cite
1.
Chen Z, Wang L. The clinical significance of UBE2C gene in progression of renal cell carcinoma. Eur J Histochem [Internet]. 2021 Mar. 29 [cited 2026 Jul. 1];65(2). Available from: https://www.ejh.it/ejh/article/view/3196
